She was diagnosed with alopecia areata, an autoimmune condition that disrupts regular hair growth, at just 18 months old and ...

Other JAK inhibitors used as a treatment of alopecia areata or alopecia universalis are ruxolitinib (Jakafi), and baricitinib (Olumiant). Some of these medications are used mainly for other ...

Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted ...

Younger patients with alopecia areata (AA) and those who have a history ... The JAKis used were baricitinib (n = 18), deuruxolitinib (n = 17), ritlecitinib (n = 17), upadacitinib (n = 1), and ...

Some trials are focusing on drugs that target the immune system, which is affected by different pathways to long covid.

Lilly and Incyte's already-marketed JAK inhibitor Olumiant (baricitinib) is currently in the lead among drugs for alopecia areata, with a filing due in the second half of this year after two ...

Pfizer said that Litfulo (ritlecitinib) is the first alopecia areata therapy to be cleared for use in adolescents in the EU. JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be ...

So, we now have two FDA-approved JAK inhibitors for severe alopecia areata. Summer of 2022, we saw the approval of baricitinib, which is a JAK1/2 inhibitor for adults with severe alopecia areata.

So even though he was a teenager, I was fortunately able to get him approved for baricitinib ... that even alone can show benefit in alopecia areata, but we’ve also shown that in many patients ...

Suggested remit: To appraise the clinical and cost effectiveness of Baricitinib within its marketing authorisation for treating severe or very severe alopecia areata ...

Department of Dermatology, Hebei Medical University Third Hospital, Shijiazhuang, China Alopecia areata (AA) is an autoimmune disease ... such as tofacitinib, baricitinib, and ruxolitinib, are mostly ...